Video

Role of Second Generation FLT3 Inhibitors in AML

Author(s):

Alexandra S. Wolff, PharmD, BCOP

Expert examines the status of second-generation FLT3 inhibitors in newly diagnosed AML patients and the challenge with comparing clinical trial efficacy endpoints.

Related Videos
Related Content
3D illustration of T-cells | Image Credit: © Emile - stock.adobe.com
March 26th 2025

AIM Test Could Help Predict COVID-19 Vaccine Response in Patients With CLL

Alexandra Gerlach, Associate Editor
The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma
January 31st 2025

The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma

Alexandra Gerlach, Associate Editor
Multiple myeloma cells | Image Credit: © LELISAT - stock.adobe.com
March 26th 2025

Long-Term Follow-Up Data from the CASSIOPEIA Trial Show Continued MRD, PFS Benefit in Multiple Myeloma

Alexandra Gerlach, Associate Editor
Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap
January 29th 2024

Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap

Pharmacist holding package of ibrutinib |Image Credit: © CLShebley - stock.adobe.com
March 18th 2025

Real-World Study Supports Ibrutinib Dose Reduction for Managing Adverse Events in CLL

Alexandra Gerlach, Associate Editor
Blood cancer cells | Image Credit: © stock_acc - stock.adobe.com
March 17th 2025

Elotuzumab-Based Regimen Demonstrates Efficacy in Relapsed/Refractory Multiple Myeloma

Alexandra Gerlach, Associate Editor